Additionally, Edwards received CE Mark approval for its Alterra system for congenital heart patients. The company believes this will result in quality-of-life improvements and a reduction in the ...

Edwards Lifesciences (NYSE:EW) announced Wednesday that its pivotal TRISCEND II trial for its Evoque tricuspid valve replacement (TTVR) system reached its one-year primary endpoint in patients ...

Bernstein analyst Lee Hambright upgraded Edwards Lifesciences (EW) to Market Perform from Underperform as investor expectations adjust to slower TAVR growth. The firm notes that its previous ...